More on VTRS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-4.5% Growth)
- Ratings (4.4 Score)
- Holders
- Dividends (2.7% Yield)

Upcoming Events

- Earnings (11/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Viatris Inc (NQ:VTRS)
Delayed: 18.00 -0.48 (2.6%)
Prev. Close $18.48  
Open$18.33 
52 Wk High$ 
52 Wk Low$ 
Day High$18.38 
Day Low$17.86 
P/E N/A  
EPS$ 
Volume7,217,781 

Friends, Peers and Foes (?): PCRX, LXRX, SLGL, TEVA NVO (more...)

Oct 21, 2026 08:37 AM Viatris (VTRS) PT Raised to $20 at JPMorgan
Oct 16, 2026 04:05 PM FDA approves Viatris eye drop Ryzumvi for presbyopia treatment
Oct 16, 2026 04:05 PM Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
Oct 8, 2026 12:37 PM Jefferies Downgrades Pacira Pharmaceuticals (PCRX) to Hold
Oct 8, 2026 08:38 AM Form 8-K Viatris Inc For: Oct 08
Oct 8, 2026 07:45 AM Viatris to acquire Pacira BioSciences for $1.65 billion
Oct 8, 2026 07:45 AM Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Oct 5, 2026 06:59 AM Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
Oct 5, 2026 05:42 AM Viatris (VTRS) PT Raised to $26 at UBS
Oct 2, 2026 06:04 PM Form 4 Viatris Inc For: Sep 30 Filed by: Groothuis Leo Frans
View All Articles

Entities mentioned with VTRS

View All Entities